We are excited to share groundbreaking news in the field of trichotillomania treatment. A recent study published in the prestigious Journal of Obsessive-Compulsive and Related Disorders has shown significant potential for HabitAware's Keen2 device in assisting individuals with hair pulling disorders. Furthermore, we are thrilled to announce that based on the strength of the initial study, HabitAware has received a Phase II award from the National Institutes of Health (NIH) to conduct a larger study involving up to 90 participants, which will be one of the largest interventional studies of trichotillomania conducted to date. This recognition further solidifies Keen2's status as a pioneering technology in the battle against trichotillomania.
The pilot trial conducted by researchers explored the usability, acceptability, feasibility, and preliminary efficacy of the Keen2 device and its accompanying mobile app. The study involved 15 adults diagnosed with trichotillomania who interacted with the Keen2 device and app system for a duration of 4 weeks. The results highlighted the device's potential to reduce hair pulling severity. Participants in the Keen2 device and app condition reported high usability, acceptability, and perceived efficacy of the system. The combination of the device and Habit Reversal Training (HRT) app demonstrated a significant reduction in hair pulling severity.
Phase II NIH Award
HabitAware has been granted a Phase II award from the NIH to conduct an expanded study involving 70 participants and longer research period This substantial research undertaking will delve deeper into the efficacy of the Keen2 device and app system. Additional features being developed and tested to extend the work in Phase I include improved gesture detection, stimulus control predictive alerts for pulling episodes, and treatment professional portal access.
Implications and Benefits
Trichotillomania, characterized by the repetitive pulling of one's hair, can have profound emotional and social consequences. Habit Reversal Training (HRT) has been recognized as an effective treatment, but its accessibility and efficacy have been limited by lack of access and difficulty in implementation. The Keen2 device and app system help address these challenges, offering a discreet, wrist-worn motion detection device that enhances awareness and facilitates self-administered HRT.
By leveraging cutting-edge technology, HabitAware aims to make trichotillomania treatment more accessible, empowering individuals to overcome hair pulling and its associated distress.
The Phase II NIH award represents an exciting milestone for HabitAware and the trichotillomania community. With a larger sample size and an extended timeframe, the forthcoming study will offer valuable insights into the efficacy and long-term impact of the Keen2 device and app system. This research endeavor reinforces HabitAware's commitment to evidence-based solutions and its dedication to improving the lives of those affected by trichotillomania.